Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Baker Bros. Advisors and related entities filed Amendment No. 33 to their Schedule 13D on Incyte, updating their beneficial ownership and recent option activity. The adviser and its GP report beneficial ownership of 30,865,077 Incyte shares, or 15.4% of the common stock, while Julian and Felix Baker each report beneficial ownership of just over 31.2 million shares, or 15.6% of the class.
The amendment reflects the adviser’s acquisition of 15,000 Incyte shares on May 8, 2026 through the exercise of options at $84.53 per share, for total consideration of $1,267,950. The options were held directly by Julian C. Baker in connection with his board service, but fund and adviser policies assign the economic benefit and investment power over these director compensation awards to the Baker Brothers funds.
To fund the exercise, the adviser drew $106,395 on a revolving note for Fund 667 and $1,161,555 on a separate revolving note for the Life Sciences fund. Both notes accrue interest at 4.62% per year and mature on May 1, 2053, or earlier if the acquired Incyte shares are sold. The filing reiterates that the Baker entities hold Incyte primarily for investment purposes and may increase or decrease their position over time, while currently stating no specific plans for extraordinary corporate transactions with the company.
INCYTE CORP insiders linked to Baker Bros. reported routine equity compensation activity. Entities associated with 667, L.P. and Baker Brothers Life Sciences LP exercised in total 30,000 non-qualified stock options at an exercise price of $84.53 per share, receiving the same number of Incyte common shares.
The options were originally granted to director Julian C. Baker for board service, but under advisory policies he has no direct pecuniary interest in these awards or the shares issued. The related funds and their affiliates instead hold indirect proportionate pecuniary interests, while Baker Bros. Advisors LP has voting and dispositive power over these securities.
After these exercises, the funds report indirect holdings of 28,203,718 and 2,833,039 Incyte shares, alongside direct holdings of 281,190 and 278,773 shares by Julian and Felix Baker and 33,410 shares held by FBB Associates. No open-market purchases or sales are disclosed in this filing.
INCYTE CORP executive vice president and chief financial officer Suketu Upadhyay received new equity awards as part of his compensation. He was granted 26,343 restricted stock units, vesting 25% annually over four years and settling one-for-one in common shares.
He also received 13,171 performance shares, which can deliver up to 200% of one common share each based on relative total shareholder return over a three-year period beginning January 1, 2026, with earned shares vesting on the third anniversary of the grant. In addition, he was granted 38,429 stock options with a $97.14 exercise price, vesting 25% after one year and the remainder in monthly installments over the next three years, and expiring on May 4, 2036.
INCYTE CORP executive Suketu Upadhyay, EVP & Chief Financial Officer, filed an initial Form 3 as a reporting person. The filing lists no transactions, no derivative positions and no holding entries, making this a routine regulatory ownership registration for a new insider officer.
Incyte Corp ownership disclosure: Vanguard Capital Management reports beneficial ownership of 12,591,630 shares of Incyte common stock, representing 6.32% of the class as reported. The filing shows sole voting power for 1,661,564 shares and sole dispositive power for 12,591,630 shares. The disclosure attributes holdings to Vanguard Capital Management LLC and affiliated Vanguard investment divisions and notes these holdings include securities held by Vanguard funds and managed accounts. The filing is signed by Ashley Grim on 04/30/2026 with the reported beneficial-ownership figures shown as of 03/31/2026.
Incyte Corporation is asking shareholders to elect eight directors, approve an advisory vote on executive pay and ratify Ernst & Young LLP as auditor at its 2026 annual meeting. The proxy highlights 2025 total revenue of $5.14 billion, up 21%, with net product sales of $4.35 billion, up 20%. Jakafi generated $3.09 billion in 2025 sales, while non-Jakafi products reached $1.26 billion, a 53% increase. Opzelura contributed $678 million, Niktimvo $152 million, Monjuvi/Minjuvi $145 million, Zynyz $66 million, Iclusig $134 million and Pemazyre $87 million. The filing emphasizes a broad late-stage pipeline, including mutCALR antibody INCA033989, KRASG12D inhibitor INCB161734, TGFβR2xPD‑1 bispecific INCA33890 and JAK1 inhibitor povorcitinib, with expectations of 14 pivotal trials underway by the end of 2026 and multiple regulatory submissions across hematology, oncology and inflammation and autoimmunity, alongside a pay-for-performance executive compensation program heavily weighted to performance shares.
Incyte Corporation is asking shareholders to elect eight directors, approve an advisory vote on executive pay and ratify Ernst & Young LLP as auditor at its 2026 annual meeting. The proxy highlights 2025 total revenue of $5.14 billion, up 21%, with net product sales of $4.35 billion, up 20%. Jakafi generated $3.09 billion in 2025 sales, while non-Jakafi products reached $1.26 billion, a 53% increase. Opzelura contributed $678 million, Niktimvo $152 million, Monjuvi/Minjuvi $145 million, Zynyz $66 million, Iclusig $134 million and Pemazyre $87 million. The filing emphasizes a broad late-stage pipeline, including mutCALR antibody INCA033989, KRASG12D inhibitor INCB161734, TGFβR2xPD‑1 bispecific INCA33890 and JAK1 inhibitor povorcitinib, with expectations of 14 pivotal trials underway by the end of 2026 and multiple regulatory submissions across hematology, oncology and inflammation and autoimmunity, alongside a pay-for-performance executive compensation program heavily weighted to performance shares.
Incyte delivered a much stronger quarter, with Q1 2026 revenue of $1.27 billion, up from $1.05 billion a year ago, driven by growth across its oncology and dermatology portfolio. Net sales of key products included JAKAFI $757.8 million and OPZELURA $143.0 million, with NIKTIMVO and ZYNYZ also contributing higher sales.
Net income nearly doubled to $303.3 million from $158.2 million, helped by higher product and royalty revenue and a much lower effective tax rate of 11.7% versus 32.4%. Diluted earnings per share rose to $1.47 from $0.80. Operating cash flow increased to $369.4 million, and cash and cash equivalents reached $3.46 billion, supporting a solid balance sheet with total assets of $7.34 billion.
The company recorded $23.2 million of asset impairment and disposal costs tied to the sale of downtown Wilmington properties and continues to carry $110.0 million in acquisition-related contingent consideration. Incyte also accrued about $245.9 million for potential additional Medicaid rebates if OPZELURA is treated as a line extension of JAKAFI, which currently increases OPZELURA gross-to-net deductions by approximately 8.4%.
Incyte delivered a much stronger quarter, with Q1 2026 revenue of $1.27 billion, up from $1.05 billion a year ago, driven by growth across its oncology and dermatology portfolio. Net sales of key products included JAKAFI $757.8 million and OPZELURA $143.0 million, with NIKTIMVO and ZYNYZ also contributing higher sales.
Net income nearly doubled to $303.3 million from $158.2 million, helped by higher product and royalty revenue and a much lower effective tax rate of 11.7% versus 32.4%. Diluted earnings per share rose to $1.47 from $0.80. Operating cash flow increased to $369.4 million, and cash and cash equivalents reached $3.46 billion, supporting a solid balance sheet with total assets of $7.34 billion.
The company recorded $23.2 million of asset impairment and disposal costs tied to the sale of downtown Wilmington properties and continues to carry $110.0 million in acquisition-related contingent consideration. Incyte also accrued about $245.9 million for potential additional Medicaid rebates if OPZELURA is treated as a line extension of JAKAFI, which currently increases OPZELURA gross-to-net deductions by approximately 8.4%.
Incyte Corporation reported strong first quarter 2026 results with double‑digit growth in sales and earnings. Total revenue reached $1.27 billion, up 21% from Q1 2025, driven by total net sales of $1.10 billion, a 20% increase.
Flagship cancer drug Jakafi generated net sales of $758 million, up 7%, while Opzelura cream grew 20% to $143 million. Hematology and oncology portfolio net sales more than doubled to $204 million, helped by rapid growth in Niktimvo, Monjuvi/Minjuvi and Zynyz.
GAAP operating income rose to $301.1 million and GAAP net income to $303.3 million, with diluted GAAP EPS of $1.47 and non‑GAAP diluted EPS of $1.81. The company ended the quarter with $4.0 billion in cash, cash equivalents and marketable securities and reaffirmed its 2026 guidance, including total net sales of $4.77–$4.94 billion. Management also highlighted late‑stage pipeline momentum, including 10 Phase 3 studies underway, positive Phase 3 results for povorcitinib in vitiligo, an accepted NDA in hidradenitis suppurativa and multiple anticipated approvals and launches from mid‑2026 into early 2027.
Incyte Corporation reported strong first quarter 2026 results with double‑digit growth in sales and earnings. Total revenue reached $1.27 billion, up 21% from Q1 2025, driven by total net sales of $1.10 billion, a 20% increase.
Flagship cancer drug Jakafi generated net sales of $758 million, up 7%, while Opzelura cream grew 20% to $143 million. Hematology and oncology portfolio net sales more than doubled to $204 million, helped by rapid growth in Niktimvo, Monjuvi/Minjuvi and Zynyz.
GAAP operating income rose to $301.1 million and GAAP net income to $303.3 million, with diluted GAAP EPS of $1.47 and non‑GAAP diluted EPS of $1.81. The company ended the quarter with $4.0 billion in cash, cash equivalents and marketable securities and reaffirmed its 2026 guidance, including total net sales of $4.77–$4.94 billion. Management also highlighted late‑stage pipeline momentum, including 10 Phase 3 studies underway, positive Phase 3 results for povorcitinib in vitiligo, an accepted NDA in hidradenitis suppurativa and multiple anticipated approvals and launches from mid‑2026 into early 2027.
INCYTE CORP’s President and Global Head of R&D, Pablo J. Cagnoni, reported an exercise-and-sell transaction in company stock. On April 17, 2026, he exercised employee stock options to acquire a total of 18,667 shares of common stock at strike prices of $71.93 and $64.25 per share, then completed an open-market sale of 18,667 shares at an average price of $96.50 per share.
Following these transactions, he directly held 262,692 shares of INCYTE common stock. A footnote states that this amount includes 257,553 shares of common stock issuable from previously reported restricted stock units and earned performance stock units that have not yet vested, highlighting a substantial remaining equity stake tied to future service and performance conditions.